Following publication of advisories, reports of local anesthetic poisoning decreased, but reports of lidocaine poisoning and mortality increased
Term 'post-COVID-19 residual lung abnormality' should be used instead of 'interstitial lung abnormality' for describing post-COVID-19 abnormalities
Strong recommendations presented for tapinarof cream, roflumilast cream, lebrikizumab, nemolizumab with concomitant topical therapy
Cost increased monotonically with stage at diagnosis, from $462.01 per month for stage 0 to $719.97 per month for stage 4
Odds of incident T2D increased in association with each tertile increase in the PFAS mixture
AOMs linked to significant weight regain at eight weeks after drug discontinuation compared with control group
Patients with self-perceived gluten sensitivity reacted similarly to wheat, gluten, and sham challenges
Higher comorbidity index, greater number of nephrologist visits within past six months linked to higher risk for suboptimal dialysis initiation
Increase in primary end point of death, heart failure hospitalization seen in association with baseline AF for patients undergoing M-TEER
After adjustment for multiple confounding variables, chronic kidney disease linked to having fewer than 20 teeth
Both guselkumab regimens superior to placebo
30.5 percent of school principals report that their district mandated school screening; rates of screening higher in larger schools
High levels of anxiety, depression, stigma, and impaired QoL reported by many patients; all linked to perceptions of illness